Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

GSK research aims to unlock P-med sales

GlaxoSmithKline (GSK) has unveiled new research to help pharmacists “unlock behind-the-counter sales".

GSK said the research has revealed opportunities to accelerate the growth of the pharmacy-only section of the market through “optimising the back wall”.

Paul Griffith, senior manager, global shopper insights at GSK, said prescriptions are a “driving factor” for shoppers to visit the pharmacy, which highlights a “key opportunity” to secure unplanned purchases.

“We suggest clear signage and in-store communications to encourage shoppers to speak to the pharmacist about their needs,” Mr Griffith said.

He also recommended merchandising the back wall in a way that mirrors the healthcare aisle. "For example, showing clear sub-categories and featuring seasonal products," Mr Griffith added.

The 'back wall project' is part of GSK’s ‘Pharmacy of the Future’ initiative.

For more information, contact your local GSK sales representative.

Will you order this product?

Related Content

Topics



Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now
UsernamePublicRestriction

Register

CD008650

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel